Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer”[1]. The exploratory analysis evaluated the impac...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Data Brief
Autori principali: Monk, Bradley J., Herzog, Thomas J., Wang, George, Triantos, Spyros, Maul, Scott, Knoblauch, Roland, McGowan, Tracy, Shalaby, Waleed S.W., Coleman, Robert L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2020
Soggetti:
Medicine and Dentistry
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7178483/
https://ncbi.nlm.nih.gov/pubmed/32346557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2020.105465
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi